Received Apr 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RSV | RSV (AREXVY) | GLAXOSMITHKLINE BIOLOGICALS | UNK | UNK | — |
problems with both eyes including a lot of goop in one eye; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of eye discharge in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced eye discharge (Verbatim: problems with both eyes including a lot of goop in one eye). The outcome of the eye discharge was not resolved. The reporter considered the eye discharge to be related to Arexvy. The company considered the eye discharge to be related to Arexvy. Additional Information: GSK Receipt Date: 02-APR-2025 This case was reported by a patient via interactive digital media. The reporter reported that GlaxoSmithKline was about money. The reporter was shocked how much they changed medicare part, then the reporter problems with both eyes including a lot of goop in one eye. The reporter stated that it turned a mistake getting RSV.